Platinum Rating recognizes Samsung Biologics' strategic sustainability performance

白金评级认可三星生物制品的战略可持续性表现

Samsung Biologics ranked in the top one percent of more than 100,000 companies

三星生物制品在10万多家公司中排名前1%

INCHEON, South Korea, Jan. 22, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced that the company was awarded the EcoVadis' Platinum Sustainability Rating, the highest recognition given, for the company's sustainability management..

韩国仁川，2024年1月22日/PRNewswire/--三星生物制品（KRX:207940.KS），一家全球合同开发和制造组织（CDMO），今天宣布该公司被授予EcoVadis白金可持续性评级，这是对该公司可持续性管理的最高认可。。

The Platinum Rating places Samsung Biologics in the top one percent of the over 100,000 companies assessed by EcoVadis, a global evaluation platform that assesses the corporate social responsibility performances of companies in four main areas: Environment, Labor & Human Rights, Ethics, and Sustainable Procurement.

在EcoVadis评估的10万多家公司中，三星生物制品（Samsung Biologics）获得白金评级，位列前1%。EcoVadis是一个全球评估平台，评估公司在四个主要领域的企业社会责任表现：环境、劳动与人权、道德和可持续采购。

Samsung Biologics received the Gold Sustainability Rating in 2022..

三星生物制品公司于2022年获得可持续发展金奖。。

'The Platinum Rating underscores our sustainability leadership and reflects our unwavering commitment to decarbonization, ethics, and responsible business practices,' said John Rim, CEO and President of Samsung Biologics. 'We understand that sustainability is increasingly important to all our customers and this latest accreditation reaffirms our mission in creating a healthier future for society through better services and business practices.'.

三星生物制品（Samsung Biologics）首席执行官兼总裁约翰·里姆（JohnRim）说，白金评级突显了我们的可持续发展领导力，反映了我们对脱碳、道德和负责任的商业实践的坚定不移的承诺我们理解，可持续性对我们所有的客户来说都越来越重要，这一最新的认证重申了我们的使命，即通过更好的服务和商业实践，为社会创造更健康的未来。”。

Samsung Biologics has been publishing annual Environmental, Social, and Governance reports, outlining its green strategies towards decarbonization and efforts to engage suppliers to minimize potential social and ethical risks. The company is committed to achieving zero greenhouse gas emissions and 100% renewable energy across its sites and supply chains by 2050..

三星生物制品公司（Samsung Biologics）一直在发布年度环境、社会和治理报告，概述其脱碳绿色战略，并努力吸引供应商将潜在的社会和道德风险降至最低。该公司致力于到2050年实现温室气体零排放，并在其工厂和供应链中实现100%的可再生能源。。

Samsung Biologics is also a member of the Sustainable Markets Initiative (SMI) and was the first CDMO to receive the SMI's Terra Carta Seal, in recognition of the company's efforts to drive innovation and demonstrate commitment to the creation of sustainable markets. Samsung Biologics has also joined global initiatives, including the Sustainable Aviation Buyers Alliance and the United Nations Global Compact..

三星生物制品（Samsung Biologics）也是可持续市场倡议（SMI）的成员，也是第一个获得SMI Terra Carta印章的CDMO，以表彰该公司努力推动创新并致力于创建可持续市场。三星生物制品也加入了全球倡议，包括可持续航空购买者联盟和联合国全球契约。。

For more details and updates on our sustainability efforts, please visit https://samsungbiologics.com/esg/our-commitment

有关我们可持续发展工作的更多详细信息和最新信息，请访问https://samsungbiologics.com/esg/our-commitment

About Samsung Biologics Co., Ltd.

关于三星生物制品有限公司。

Samsung Biologics (KRX: 207940.KS) is a fully integrated, end-to-end CDMO service provider, offering seamless development and manufacturing solutions from cell line development to final aseptic fill/finish as well as laboratory testing support for the biopharmaceutical products we manufacture. Our state-of-the-art facilities are cGMP compliant with bioreactors ranging from small to large scales to serve varying client needs.

三星生物制品（KRX:207940.KS）是一家完全集成的端到端CDMO服务提供商，为我们制造的生物制药产品提供从细胞系开发到最终无菌填充/表面处理的无缝开发和制造解决方案，以及实验室测试支持。我们最先进的设施符合cGMP，生物反应器的规模从小到大不等，以满足不同的客户需求。

To maximize our operational efficiency and expand our capabilities in response to growing biomanufacturing demand, Samsung Biologics recently completed Bio Campus I with Plant 4 offering a combined 604KL total capacity, and launched Bio Campus II with the construction of Plant 5, which will be operational in April 2025 adding 184KL biomanufacturing capacity.

为了最大限度地提高我们的运营效率并扩大我们的能力，以应对不断增长的生物制造需求，三星生物制品公司最近完成了生物园区一期工程，其中4号工厂的总容量为604KL，并启动了生物园区二期工程，其中5号工厂将于2025年4月投入运营，增加了184KL的生物制造能力。

Additionally, Samsung Biologics America enables the company to work in closer proximity to clients based in the U.S. and Europe. We continue to upgrade our capabilities to accommodate our clients by investing in technologies such as an antibody-drug conjugate (ADC) facility, a dedicated mRNA manufacturing facility, and additional aseptic filling capacity.

此外，三星生物制品美国公司使该公司能够更接近美国和欧洲的客户。我们通过投资抗体-药物偶联物（ADC）设施、专用mRNA制造设施和额外的无菌灌装能力等技术，继续升级我们的能力，以适应客户。

As a sustainable CDMO partner of choice, we are committed to on-time, in-full delivery of the products we manufacture with our flexible manufacturing solutions, operational excellence, and proven expertise..

作为可持续发展的CDMO首选合作伙伴，我们致力于通过灵活的制造解决方案、卓越的运营能力和久经考验的专业技能，按时、全面交付我们制造的产品。。

Samsung Biologics Media Contact

三星生物制品媒体联系人

Claire Kim, Head of Marketing Communications

Claire Kim，营销传播主管

[email protected]

[受电子邮件保护]

SOURCE Samsung Biologics

来源：三星生物制品